QIAGEN N.V.

QGENSEC EDGAR

Biological Products, (No Diagnostic Substances)(P7)CIK: 1015820

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue from Contract with Customer, Excluding Assessed Tax	$2.1B	$2.3B	$1.9B	$1.5B	$1.5B
Cost of Goods and Services Sold	$757.0M	$800.8M	$637.6M	$521.2M	$500.9M
Gross Profit	$1.4B	$1.5B	$1.2B	$1.0B	$1.0B
Operating Expenses	$853.1M	$820.7M	$846.3M	$1.0B	$734.4M
Operating Income (Loss)	$531.5M	$630.1M	$386.4M	-$26.1M	$266.6M
Interest Expense	—	$54.5M	$71.3M	$74.2M	$67.3M
Nonoperating Income (Expense)	-$18.9M	-$4.3M	$53.0M	-$51.6M

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Assets	$6.1B	$6.3B	$6.1B	$5.9B	$5.2B
Assets, Current	$2.1B	$2.4B	$2.1B	$1.6B	$1.6B
Cash and Cash Equivalents, at Carrying Value	$668.1M	$730.7M	$880.5M	$598.0M	$623.6M
Accounts Receivable, after Allowance for Credit Loss, Current	$381.9M	$323.8M	$362.1M	$380.5M	$385.1M
Inventory, Net	$398.4M	$358.0M	$327.5M	$291.2M	$170.7M
Liabilities, Current	$1.1B	$974.5M	$1.5B	$572.2M	$951.3M
Long-term Debt	$1.5B	$1.9B	$1.9B	$1.9B

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Net Cash Provided by (Used in) Operating Activities	$715.3M	$639.0M	$457.8M	$330.8M	$359.5M
Net Cash Provided by (Used in) Investing Activities	-$726.8M	-$202.4M	-$443.3M	-$222.3M	-$211.4M
Net Cash Provided by (Used in) Financing Activities	-$125.8M	-$150.4M	-$50.1M	-$639.1M	$360.4M
Payments to Acquire Property, Plant, and Equipment	$129.2M	$189.9M	$132.8M	$118.0M	$109.8M
Payments for Repurchase of Common Stock	$0.00	$100.0M	$64.0M	$74.5M	$104.7M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)